[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature
Tóm tắt
Từ khóa
Tài liệu tham khảo
Eiber, 2017, Prostate-specific membrane antigen ligands for imaging and therapy, J Nucl Med, 58, 67S, 10.2967/jnumed.116.186767
Hofman, 2018, Prostate-specific membrane antigen PET: Clinical utility in prostate cancer, normal patterns, pearls, and pitfalls, Radiographics, 38, 200, 10.1148/rg.2018170108
Lin, 2019, Comparing the staging/restaging performance of 68Ga-labeled prostate-specific membrane antigen and 18F-choline PET/CT in prostate cancer: a systematic review and meta-analysis, Clin Nucl Med, 44, 365, 10.1097/RLU.0000000000002526
Wester, 2019, PSMA-targeted radiopharmaceuticals for imaging and therapy, Semin Nucl Med, 49, 302, 10.1053/j.semnuclmed.2019.02.008
Gafita, 2021, Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study, Lancet Oncol, 22, 1115, 10.1016/S1470-2045(21)00274-6
Bianchi, 2021, Multicenter external validation of a nomogram for predicting positive prostate-specific membrane antigen/positron emission tomography scan in patients with prostate cancer recurrence, Eur Urol Oncol
Bianchi, 2020, Predictive accuracy and clinical benefit of a nomogram aimed to predict 68 Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database, Eur J Nucl Med Mol Imaging, 47, 2100, 10.1007/s00259-020-04696-z
Bianchi, 2019, How does 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?, Int J Urol, 26, 804, 10.1111/iju.14012
CASP. Critical Appraisal Skills Programme. https://casp-uk.b-cdn.net/wp-content/uploads/2018/03/CASP-Diagnostic-Checklist-2018_fillable_form.pdf.
Dietlein, 2017, PSA-stratified performance of 18F-and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer, J Nucl Med, 58, 947, 10.2967/jnumed.116.185538
Fendler, 2019, Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer, Clin Cancer Res, 25, 7448, 10.1158/1078-0432.CCR-19-1050
Dietlein, 2020, Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer, J Nucl Med, 61, 729, 10.2967/jnumed.119.234898
Rauscher, 2020, Matched-pair comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy, J Nucl Med, 61, 51, 10.2967/jnumed.119.229187
Scobioala, 2021, Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions, Ann Nucl Med, 35, 628, 10.1007/s12149-021-01606-7
Jansen, 2021, Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the Phoenix criteria for biochemical recurrence after curative radiotherapy, Eur Urol Oncol, 4, 821, 10.1016/j.euo.2020.01.002
Baas, 2021, Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection, Prostate Cancer Prostatic Dis
Morawitz, 2021, PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: comparison of detection rates and therapeutic implications, Eur J Radiol, 136, 10.1016/j.ejrad.2021.109556
Koerber, 2021, Predicting the risk of metastases by PSMA-PET/CT—evaluation of 335 men with treatment-naïve prostate carcinoma, Cancers (Basel), 13, 1508, 10.3390/cancers13071508
Hoberück, 2021, Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis, EJNMMI Res, 11, 109, 10.1186/s13550-021-00845-z
Pattison, 2022, Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer, Eur J Nucl Med Mol Imaging, 49, 763, 10.1007/s00259-021-05520-y
Kroenke, 2021, Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor-related uptake and tumor positivity, J Nucl Med, 62, 1082, 10.2967/jnumed.120.251447
Grünig, 2021, Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging, Eur J Nucl Med Mol Imaging, 48, 4483, 10.1007/s00259-021-05424-x
Arnfield, 2021, Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation, Eur J Nucl Med Mol Imaging, 48, 4495, 10.1007/s00259-021-05456-3
Wondergem, 2021, Matched-pair comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 prostate cancer patients; Inter-reader agreement and lesion detection rate of suspected lesions, J Nucl Med, 62, 1422, 10.2967/jnumed.120.258574
Sartor, 2021, Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer, N Engl J Med, 385, 1091, 10.1056/NEJMoa2107322
Hofman, 2021, [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial, Lancet, 397, 797, 10.1016/S0140-6736(21)00237-3
Schmuck, 2017, Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer, Eur J Nucl Med Mol Imaging, 44, 960, 10.1007/s00259-017-3669-5
Kunikowska, 2020, 68Ga-PSMA PET/CT in recurrence prostate cancer. Should we perform delayed image in cases of negative 60 minutes postinjection examination?, Clin Nucl Med, 45, e213, 10.1097/RLU.0000000000002966
Hoffmann, 2020, Dual-time point [68Ga]Ga-PSMA-11 PET/CT hybrid imaging for staging and restaging of prostate cancer, Cancers (Basel), 12, 1, 10.3390/cancers12102788
Rodnick, 2020, Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target, EJNMMI Radiopharm Chem, 5, 25, 10.1186/s41181-020-00106-9
Uprimny, 2021, Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET/CT, J Nucl Med, 62, 1550, 10.2967/jnumed.120.261866
Iravani, 2017, 68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer, Cancer Imaging, 17, 31, 10.1186/s40644-017-0133-5
Heußer, 2017, Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI, PLoS One, 12, e0183329, 10.1371/journal.pone.0183329
Bailey, 2018, Accuracy of dose calibrators for 68Ga PET imaging: unexpected findings in a multicenter clinical pretrial assessment, J Nucl Med, 59, 636, 10.2967/jnumed.117.202861
Ceci, 2021, E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET, Eur J Nucl Med Mol Imaging, 48, 1626, 10.1007/s00259-021-05245-y